News Releases | Upcoming Events | Webcast/Presentation Archive

View printer-friendly version << Back

T.J. Samson is the First Hospital in Kentucky to Adopt Patient SafetyNet™

12/01/15

IRVINE, Calif. & GLASGOW, Ky.--(BUSINESS WIRE)--Dec. 1, 2015-- Masimo (NASDAQ: MASI) and T.J. Samson Community Hospital announced that the hospital is the first in Kentucky to install Masimo Patient SafetyNet, a remote monitoring and clinician notification system.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151201005787/en/

T.J. Samson is the First Hospital in Kentucky to Adopt Patient SafetyNet™ (Photo: Business Wire)

T.J. Samson is the First Hospital in Kentucky to Adopt Patient SafetyNet™ (Photo: Business Wire)

“Patient safety is my top priority,” said Bud Wethington, Chief Executive Officer of T.J. Samson Community Hospital. “We did a lot of research in finding the system that was right for us. After trying several other systems and visiting another hospital that was utilizing Patient SafetyNet, we found it to be a perfect fit for our hospital. The installation was easier than anticipated and we were up and running in a very short amount of time.”

Masimo Patient SafetyNet works in conjunction with Masimo beside monitors which provide continuous and non-invasive monitoring of oxygenation, pulse rate and respiration, and other parameters. When changes occur in the measured values, which may indicate deterioration in the patient’s condition, in addition to bedside alerts, Patient SafetyNet automatically sends wireless alerts directly to clinicians. Continuous patient surveillance with Patient SafetyNet has been shown to reduce the need for rescue events and intensive care unit transfers in hospitals and, as a result, can reduce costs related to these events.1,2

“We are so impressed when we see a community hospital equip their team with the latest in technology to better monitor their patients and improve patient safety practices,” said Joe Kiani, Founder and CEO of Masimo. “There are much larger hospitals throughout the country that have yet to install wireless notification systems for supplemental monitoring.”

@MasimoInnovates | #Masimo

1 Taenzer A.H., Pyke J.B., McGrath S.P., Blike G.T. Anesthesiology. 2010 Feb;112(2):282-7.

2 Taenzer A, Blike G, McGrath S, Pyke J, Herrick M, Renaud C, Morgan J. “Postoperative Monitoring - The Dartmouth Experience.” Anesthesia Patient Safety Foundation Newsletter Spring-Summer 2012. Available online.

About T.J. Samson Community Hospital

Since 1929, T.J. Samson Community hospital has offered a variety of health services to the region, including acute care; preventive testing and treatment; community outreach activities; and partnerships with local heath care providers, civic organizations, and public schools. The hospital has undergone several expansions, including its most recent addition—a new wing to house an ultramodern labor and delivery floor, emergency department, cardiology laboratory, and intensive care unit. In May 1997, the hospital was designated as the site for one of Kentucky’s congressionally mandated Family Practice Residency Programs and is now home to the University of Louisville Glasgow/Barren County Family Medicine Residency. Today, T.J. Samson Community Hospital is a 196-bed, acute-care facility, including sixteen skilled-care beds and the T.J. Health Pavilion, providing outpatient services and physicians’ offices. For more information, please visit www.tjsamson.org.

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through-Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). The indications for EMMA include the following: 1) The EMMA Emergency Capnometer Monitor measures, displays and monitors carbon dioxide concentration and respiratory rate during anesthesia, recovery and respiratory care. It may be used in the operating suite, intensive care unit, patient room, clinic, emergency medicine and emergency transport settings for adult, pediatric and infant patients. 2) The EMMA Emergency Capnometer Analyzer measures and displays carbon dioxide concentration and respiratory rate during anesthesia, recovery and respiratory care. It may be used in the operating suite, intensive care unit, patient room, clinic, emergency medicine and emergency transport settings for adult, pediatric and infant patients. Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Source: Masimo

T.J.Samson (Media Contact)
Bart Logsdon, 270-651-4618
blogsdon@tjsamson.org
or
Masimo (Media Contact)
Irene Paigah, 858-859-7001
irenep@masimo.com